NSI-566 is under clinical development by Palisade Bio and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NSI-566’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 08 May 2021 increased NSI-566’s Phase Transition Success Rate (PTSR) for Chronic Spinal Cord Injury.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NSI-566 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NSI-566 overview

NSI-566 is under development for the treatment of Amyotrophic lateral sclerosis (ALS), chronic spinal cord injury (SCI) traumatic brain injury, and paralysis due to ischemic stroke. It is administered through intraspinal (intrathecally) route in ALS and through intracerebral route in stroke. It is developed based on human neural stem cell technology.

It was under development for the treatment of glioblastoma, acute spinal cord injury, Huntington's disease, ischemic spastic paraplegia, multiple sclerosis, optic neuritis, peripheral nerve injury, diabetic neuropathy, lysosomal diseases, Parkinson’s disease and cerebral palsy.

Palisade Bio overview

Palisade Bio (Palisade), formerly, Seneca Biopharma Inc is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peripheral nerve injury, diabetic neuropathy, lysosomal disease, Parkinson’s disease, huntington’s disease and cerebral palsy, among others. It provides drug treatment for depressive disorder, cognitive complication due to diabetes, post traumatic stress disorder, neurodegeneration and anti aging. The company develops methods to generate replacement cells from neural stem cells. It conducts investigational and discovery research on proprietary neural stem cell lines, neurogenic small molecule screening platform and neurogenic small molecule portfolio. Palisade is headquartered in Germantown, Maryland, the US.

Quick View NSI-566 LOA Data

Report Segments
  • Innovator
Drug Name
  • NSI-566
Administration Pathway
  • Intracerebral
  • Intrathecal
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genetic Disorders
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
Key Developers
  • Sponsor Company: Palisade Bio
  • Originator: Palisade Bio
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.